David Basanta Gutierrez

Ars Technica - Path to precision: Targeted cancer drugs go from table to trials to bedside

https://arstechnica.com/science/2024/08/precision-cancer-treatments/

I just hope that people working on this have more ambition than just trying to find as many drugs as a patient can take at a given time simultaneously #SomaticEvolution

Path to precision: Targeted cancer drugs go from table to trials to bedside

What started in a scientist's dining room is now in tissue-agnostic combo trials.

Ars Technica
Aug 6, 2024 at 3:24pmWeb
Show threadAndrei KucharavyAug 7, 2024

@david a proper evolution-blocking targeted therapy is possible, but research to make it possible would require that the cancer gene dogma dies, or at least its defenders on grant review boards.

I left the field in 2018 in large part for that reason.

Show threadDavid Basanta GutierrezAug 7, 2024
@andrei_chiffa sorry to hear that you left the field